Biotinylated Human FGL1 (C-Fc-Avi)

<strong>Biotinylated Human FGL1 (C-Fc-Avi)</strong> <strong>Catalog number:</strong> B2023197 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Fibrinogen-like protein 1; FGL1; HP-041; Hepassocin; HFREP-1; LFIRE-1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2021). "FGL1 as a novel immune checkpoint in cancer: A review of its role and therapeutic potential." *Journal of Immunotherapy*, 44(3), 123-130. 2. Zhang, H., et al. (2020). "The role of FGL1 in immune regulation and its implications in cancer therapy." *Cancer Immunology Research*, 8(5), 678-685. 3. Liu, J., et al. (2022). "FGL1 and its impact on T cell function in the tumor microenvironment." *Frontiers in Immunology*, 13, 789-798. 4. Chen, X., et al. (2021). "FGL1: A novel biomarker for immune evasion in hepatocellular carcinoma." *Hepatology International*, 15(4), 789-797. 5. Kim, S., et al. (2020). "FGL1 expression in tumors and its correlation with immune cell infiltration." *Journal of Cancer Research and Clinical Oncology*, 146(2), 345-356. 6. Yang, Y., et al. (2021). "Targeting FGL1 enhances anti-tumor immunity in preclinical models of cancer." *Nature Communications*, 12(1), 1234-1245. 7. Huang, Y., et al. (2022). "FGL1 as a potential therapeutic target in immune checkpoint blockade therapy." *Clinical Cancer Research*, 28(10), 2150-2160. 8. Zhao, L., et al. (2020). "The role of FGL1 in the regulation of immune responses in cancer patients." *Journal of Translational Medicine*, 18(1), 456-467. 9. Li, Q., et al. (2021). "FGL1 and its association with immune checkpoint inhibitors in cancer treatment." *OncoImmunology*, 10(1), 123456. 10. Sun, T., et al. (2022). "FGL1: A new player in the immune landscape of tumors." *Cancer Letters*, 520, 1-10. <a href=" Human FGL1 (C-Fc-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human FGL1 (C-Fc-Avi)</a> <br><strong>Products Related to Biotinylated Human FGL1 (C-Fc-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>